Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States

Conclusion:
Based on real-world data, when any of the evaluated NOACs are used instead of warfarin for treatment of patients with acute VTE, annual medical costs are reduced. Of the NOACs, apixaban has the greatest real-world medical cost avoidance, as its use is associated with substantial reductions in both VTE and MB event rates.

Source: Clinical and Applied Thrombosis/Hemostasis - December 9, 2015 Category: Hematology Authors: Amin, A., Bruno, A., Trocio, J., Lin, J., Lingohr-Smith, M. Tags: Review Source Type: research